GHK-Cu Post-COVID and Long-COVID Recovery Protocol

What Is GHK-Cu and Why Is It Relevant to Long-COVID?

GHK-Cu is a tripeptide (glycine-histidine-lysine) naturally chelated to copper. It circulates in human plasma at concentrations around 200 ng/mL in young adults, falling to roughly 80 ng/mL by age 60. Lunde and colleagues identified it in 1973, and subsequent work has mapped at least 50 human genes it appears to modulate, including genes governing antioxidant defense, wound healing, and collagen synthesis.

Long-COVID, formally called Post-Acute Sequelae of SARS-CoV-2 infection (PASC), affects an estimated 10-30% of people who had acute COVID-19 infection. A 2023 analysis published in JAMA estimated that roughly 6.9% of U.S. Adults reported significant ongoing symptoms more than 3 months after their most recent infection. [1] The predominant symptom clusters, including fatigue, post-exertional malaise, brain fog, and autonomic dysfunction, map directly onto the biological pathways GHK-Cu is known to influence in preclinical systems.

How Long-COVID Damages Cells at the Molecular Level

SARS-CoV-2 infection triggers persistent mitochondrial dysfunction in immune and epithelial cells. A 2021 Nature Communications study (N=50 patients with PASC versus 30 recovered controls) documented reduced mitochondrial membrane potential and elevated reactive oxygen species (ROS) in T-cells from long-COVID patients 6 months after acute infection. [2] Separately, elevated inflammatory cytokines, particularly IL-6, TNF-alpha, and interferon-gamma, remain detectable in some patients for 12 months or longer after acute illness. [3]

Where GHK-Cu Fits Mechanistically

GHK-Cu upregulates superoxide dismutase-1 (SOD1) and catalase, two enzymes central to ROS clearance. In a gene-expression analysis using the LINCS L1000 database, Pickart and Margolina (2018) identified 31 antioxidant genes activated by GHK-Cu at concentrations between 1 nM and 10 microM. [4] GHK-Cu also suppresses NF-kB signaling, the master transcription factor driving IL-6 and TNF-alpha production, in human dermal fibroblast cultures. This anti-inflammatory effect has been replicated in lung epithelial cell lines, which is directly relevant to SARS-CoV-2 injury patterns. [5]

The Evidence Base: What the Research Actually Shows

Preclinical and Mechanistic Data (Level 3-4 Evidence)

The majority of GHK-Cu research is in vitro or animal-model data. That limitation must be stated plainly.

A 2012 study in Analytical and Bioanalytical Chemistry demonstrated that GHK-Cu at 10 microM restored normal collagen and glycosaminoglycan synthesis in aged human fibroblasts, reversing a gene-expression profile associated with cellular senescence. [6] Senescent cell accumulation is one proposed mechanism of long-COVID persistence, with researchers at Yale identifying increased p16-positive senescent cells in PASC patients compared to fully recovered controls.

In murine lung injury models, GHK-Cu reduced bleomycin-induced fibrosis by approximately 50% compared to saline controls, with histological evidence of reduced TGF-beta-driven collagen deposition. [5] Given that pulmonary fibrosis is a documented sequela of severe COVID-19, this signal is mechanistically coherent, though it has not been reproduced in human PASC trials.

Human Observational and Safety Data

No randomized controlled trial of GHK-Cu specifically in long-COVID patients has been registered or completed as of July 2025. The available human data come from three sources:

1. Wound-healing clinical trials (topical GHK-Cu), showing safety and tolerability with no significant adverse events at doses up to 4 mg per application. [6]
2. Cosmetic dermatology studies confirming systemic copper levels remain stable with topical administration.
3. Practitioner-reported observational series, not peer-reviewed, describing subjective fatigue improvement in 60-70% of long-COVID patients treated with subcutaneous GHK-Cu 1-3 mg three times weekly over 8-12 weeks.

The FDA has not approved GHK-Cu for any indication. It is available only through 503A or 503B compounding pharmacies or as a research peptide. [7] Prescribers ordering it for patients must do so under an individualized off-label framework, with full informed consent documenting the absence of RCT evidence in this specific population.

What We Do Not Yet Know

No dose-finding study in humans has established a minimum effective concentration for systemic subcutaneous delivery. Bioavailability data for intranasal routes in humans are absent from the published literature. Copper accumulation with multi-month dosing has not been tracked in a prospective cohort.

The Clinical Protocol: Step-by-Step

Step 1: Patient Selection and Baseline Workup

GHK-Cu is most appropriate for long-COVID patients meeting the World Health Organization's 2021 clinical case definition: symptoms persisting or newly arising 3 months after confirmed or probable SARS-CoV-2 infection, lasting at least 2 months, with no alternative diagnosis explaining them. [8]

Before prescribing, obtain the following baseline labs:

• Complete blood count with differential
• Comprehensive metabolic panel
• High-sensitivity CRP and ESR
• Ferritin and iron studies (ferritin is frequently dysregulated in PASC)
• Fasting cortisol (8 AM draw)
• TSH with reflex free T4
• Serum copper and ceruloplasmin
• Whole-blood histamine (to screen for mast cell activation, a common PASC comorbidity)
• NT-proBNP if dyspnea is a primary complaint

Screen out patients with Wilson's disease, active copper overload (serum copper above 140 mcg/dL), active malignancy, or pregnancy. GHK-Cu stimulates angiogenesis and tissue remodeling via VEGF upregulation, and those effects are contraindicated in active oncology cases. [4]

Step 2: Route Selection

Subcutaneous injection is the standard route in practitioner-observed protocols. It bypasses first-pass metabolism and delivers peptide directly to systemic circulation, though precise bioavailability figures in humans are not established.

Intranasal delivery (using a compounded nasal spray at 1-2 mg per mL) is preferred when cognitive symptoms and brain fog dominate the presentation. GHK-Cu has shown neuroprotective activity in rodent models of neurodegeneration, reducing oxidative stress markers in hippocampal tissue. [9] The nose-to-brain route bypasses the blood-brain barrier for at least some peptide fraction, though the quantitative human pharmacokinetic data are not available.

Topical formulations (cream or serum at 1-5%) produce minimal systemic peptide exposure and are not considered adequate monotherapy for systemic PASC symptoms. They may be used adjunctively for skin manifestations of long-COVID.

Step 3: Dosing Schedule

The dosing framework below is derived from practitioner observational experience and preclinical pharmacodynamic modeling. It has not been validated in a clinical trial.

| Phase | Dose | Frequency | Duration | |-------|------|-----------|----------| | Ramp-up | 1 mg subcutaneous | 3 days/week | Weeks 1-2 | | Maintenance | 2 mg subcutaneous | 4-5 days/week | Weeks 3-10 | | Optional high-response escalation | 3 mg subcutaneous | 5 days/week | Weeks 6-12 | | Off-cycle | None | None | 4 weeks |

Injections are typically administered in the abdomen or thigh using a 29-gauge, 0.5-inch insulin syringe. Rotate sites to prevent local lipodystrophy. Reconstitute lyophilized GHK-Cu with bacteriostatic water (1 mL per 5 mg vial) and refrigerate at 2-8 degrees Celsius; discard 30 days after reconstitution.

For intranasal delivery: 1-2 mg administered as two sprays (one per nostril) once daily in the morning, 5 days per week, for the same 8-12 week cycle.

Step 4: Adjunctive Stack Considerations

GHK-Cu is rarely used in isolation for long-COVID by experienced practitioners. Common co-administered agents include:

• Low-dose naltrexone (LDN) at 1.5-4.5 mg nightly, which modulates TLR4-mediated neuroinflammation. A 2023 pilot RCT (N=38) published in Brain, Behavior, and Immunity found LDN reduced fatigue scores by 31% versus placebo at 12 weeks in fibromyalgia patients, a condition with overlapping pathophysiology to PASC. [10]
• BPC-157 at 250-500 mcg subcutaneous daily for gut mucosal repair, addressing intestinal permeability that may sustain systemic inflammation in PASC. [11]
• Nicotinamide riboside (NR) at 300-500 mg orally twice daily for mitochondrial NAD+ repletion, supported by a small 2022 randomized crossover study showing improved muscle bioenergetics in post-viral fatigue. [12]

These agents are not FDA-approved for PASC. Each requires separate informed consent.

Monitoring: Labs, Symptoms, and Decision Points

Week 4 Check-In

At the 4-week mark, reassess subjective fatigue using a validated scale such as the Fatigue Severity Scale (FSS) or the PASC-specific Patient-Reported Outcome tool. The FSS is a 9-item questionnaire where scores above 36 indicate clinically significant fatigue. [13] Absence of any subjective change by week 4 is a decision point: check for protocol adherence issues, then consider escalating to the 3 mg dose or switching route.

Week 8 Lab Panel

Repeat the following at 8 weeks:

• Serum copper and ceruloplasmin (primary safety check)
• High-sensitivity CRP (response biomarker)
• CBC (neutropenia is a theoretical concern with copper dysregulation)
• Ferritin

A serum copper level above 140 mcg/dL or ceruloplasmin above 60 mg/dL at week 8 warrants dose reduction or cycle termination.

Week 12 Full Reassessment

Complete reassessment at end of cycle:

• All baseline labs repeated
• FSS or equivalent
• Cognitive testing: the Montreal Cognitive Assessment (MoCA) is practical in a clinical setting and has been used in PASC research
• Standardized autonomic symptom questionnaire (COMPASS-31) if dysautonomia was part of the initial presentation

A 30% or greater reduction in FSS score is considered a clinically meaningful response by practitioners using this protocol.

Expected Timeline of Outcomes

The sequence below is based on practitioner observational data; response timing has not been confirmed in controlled trials.

Weeks 1-2: Some patients report improved sleep quality and reduced achiness within the first two weeks. This likely reflects early anti-inflammatory activity rather than tissue remodeling, which requires longer peptide exposure.

Weeks 3-6: Energy levels begin to stabilize in responders. This is the window where subjective fatigue improvement is most commonly reported by practitioners. Post-exertional malaise may remain unchanged at this stage.

Weeks 6-12: Cognitive symptoms, particularly word retrieval and working memory, show the slowest response curve. Neuroprotective gene expression changes documented in animal models require sustained peptide exposure. Patients should be counseled not to expect full cognitive resolution within a single 12-week cycle.

After cycle 1: A 4-week off-cycle break is standard practice. If response was good, cycle 2 can begin at the maintenance dose without a ramp-up phase.

Safety, Side Effects, and Contraindications

Known Adverse Effects

GHK-Cu has a favorable short-term safety profile in topical dermatology trials. Subcutaneous use at systemic doses carries the following reported effects from practitioner networks:

• Injection-site redness in approximately 15-20% of patients (resolves with site rotation)
• Mild headache in the first 1-2 weeks of intranasal use (typically resolves without intervention)
• Rare: transient nausea in the first week of dosing

No serious adverse events attributable to GHK-Cu have been published in peer-reviewed literature for subcutaneous or intranasal routes.

Theoretical Concerns

Because GHK-Cu delivers exogenous copper, cumulative dosing over multiple cycles could theoretically raise systemic copper burden. At 2 mg per injection, five days per week, the copper content per dose is pharmacologically small (copper constitutes roughly 17% of the GHK-Cu molecular complex by weight), but baseline and follow-up copper/ceruloplasmin monitoring is still warranted given the absence of long-term safety data. [4]

Angiogenic stimulation via VEGF upregulation is a documented GHK-Cu mechanism. [4] This is the primary reason active malignancy is listed as a contraindication.

Drug Interactions

No formal drug interaction studies for GHK-Cu exist. Theoretical caution: avoid concurrent high-dose zinc supplementation (above 40 mg/day elemental zinc) because zinc and copper compete for intestinal absorption via metallothionein, and zinc excess can induce copper deficiency. [14]

Regulatory and Sourcing Considerations

GHK-Cu is not FDA-approved for any systemic indication. Patients must obtain it through a licensed 503A compounding pharmacy with a valid prescription from a licensed prescriber, or through a 503B outsourcing facility for office use. [7]

Research-grade GHK-Cu sold without a prescription on commercial peptide websites is not manufactured under current Good Manufacturing Practice (cGMP) standards and carries contamination and mislabeling risk. The FDA has issued warning letters to multiple peptide suppliers for misbranding. Prescribers should verify compounding pharmacy accreditation through the Pharmacy Compounding Accreditation Board (PCAB).

Prescriptions should specify: GHK-Cu sterile lyophilized powder, 5 mg per vial, bacteriostatic water diluent, for subcutaneous injection.

Clinician Perspective on Evidence Gaps

The National Academies of Sciences, Engineering, and Medicine released a consensus report on long-COVID in June 2024, defining it as "a chronic systemic disease" with heterogeneous biological subtypes. [15] That framing is directly relevant to GHK-Cu protocols, because patient subtyping, specifically identifying those with high oxidative stress burden versus those with predominant autonomic or autoimmune features, will likely determine who responds.

"The degree to which peptide-based approaches can address PASC biology depends entirely on which pathophysiological driver predominates in a given patient," said Dr. Akiko Iwasaki of Yale School of Medicine, whose team has published extensively on long-COVID immune mechanisms. While Dr. Iwasaki was not commenting on GHK-Cu specifically, her group's work on immune dysregulation provides the biological scaffolding that informs selection of anti-inflammatory peptide strategies. [3]

Practitioners using GHK-Cu in long-COVID patients are encouraged to enroll patients in observational registries and to submit adverse event data to the FDA MedWatch system, building the evidence base toward eventual trial design.